{"id":"rivaroxaban-10-milligrams","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Bleeding"},{"rate":"0.5-2","effect":"Gastrointestinal bleeding"},{"rate":"0.1-0.5","effect":"Intracranial hemorrhage"},{"rate":"1-3","effect":"Dyspepsia"},{"rate":"1-2","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL198362","moleculeType":"Small molecule","molecularWeight":"435.89"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rivaroxaban selectively inhibits Factor Xa, a key enzyme in the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa, it prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and inhibiting clot formation. This anticoagulant effect is used to prevent and treat thrombotic events.","oneSentence":"Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:26.372Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis (DVT) prevention and treatment"},{"name":"Pulmonary embolism (PE) prevention and treatment"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT02846532","phase":"PHASE3","title":"Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-11-16","conditions":"Thrombosis","enrollment":112},{"nctId":"NCT02561923","phase":"PHASE1","title":"A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-08-27","conditions":"Healthy","enrollment":158},{"nctId":"NCT04508023","phase":"PHASE3","title":"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-08-13","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":1284},{"nctId":"NCT04504032","phase":"PHASE2","title":"A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2020-09-02","conditions":"COVID-19","enrollment":497},{"nctId":"NCT04169269","phase":"PHASE4","title":"Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban","status":"UNKNOWN","sponsor":"Florida Orthopaedic Institute","startDate":"2020-01-13","conditions":"Deep Vein Thrombosis, Venous Thromboembolism","enrollment":128},{"nctId":"NCT02555878","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-11","conditions":"Neoplasms","enrollment":841},{"nctId":"NCT03299296","phase":"PHASE3","title":"Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin","status":"UNKNOWN","sponsor":"Ahmed AbdelMoneim Hassan Ali","startDate":"2017-01-01","conditions":"Thromboses, Deep Vein, Surgery--Complications","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rivaroxaban 10 Milligrams","genericName":"Rivaroxaban 10 Milligrams","companyName":"Ahmed AbdelMoneim Hassan Ali","companyId":"ahmed-abdelmoneim-hassan-ali","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) prevention and treatment, Pulmonary embolism (PE) prevention and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}